Oncopeptides AB Registered Shs Aktie [WKN DE: A2DLU2 / ISIN: SE0009414576]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Oncopeptides AB Registered Shs

24.11.20		Program for Oncopeptides virtual Capital Markets Day on November 30 is published (PR Newswire)
24.11.20		Program for Oncopeptides virtual Capital Markets Day on November 30 is published (PR Newswire)
19.11.20		Oncopeptides: INTERIM REPORT Q3 2020 (PR Newswire)
19.11.20		Oncopeptides: INTERIM REPORT Q3 2020 (PR Newswire)
05.11.20		Oncopeptides hosts a virtual capital markets day on November 30 (PR Newswire)
05.11.20		Oncopeptides hosts a virtual capital markets day on November 30 (PR Newswire)
04.11.20		Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting (PR Newswire)
04.11.20		Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting (PR Newswire)
03.11.20		Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
03.11.20		Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
21.10.20		Nomination committee in Oncopeptides established (PR Newswire)
21.10.20		Nomination committee in Oncopeptides established (PR Newswire)
19.10.20		Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform (PR Newswire)
19.10.20		Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform (PR Newswire)
14.10.20		Oncopeptides signs € 40 million loan agreement with the EIB (PR Newswire)
14.10.20		Oncopeptides signs € 40 million loan agreement with the EIB (PR Newswire)
12.10.20		With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA (PR Newswire)
12.10.20		With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA (PR Newswire)
01.10.20		Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma (PR Newswire)
01.10.20		Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma (PR Newswire)
08.09.20		Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit (PR Newswire)
04.09.20		Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included (PR Newswire)
04.09.20		Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included (PR Newswire)
29.08.20		FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma (PR Newswire)
29.08.20		FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma (PR Newswire)
26.08.20		Oncopeptides AB: Interim Report Q2 2020 (PR Newswire)
26.08.20		Oncopeptides AB: Interim Report Q2 2020 (PR Newswire)
07.08.20		Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study (PR Newswire)
07.08.20		Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study (PR Newswire)
04.08.20		Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma (PR Newswire)
04.08.20		Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma (PR Newswire)
31.07.20		Number of shares and votes in Oncopeptides (PR Newswire)
31.07.20		Number of shares and votes in Oncopeptides (PR Newswire)
30.06.20		Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO (PR Newswire)
30.06.20		Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO (PR Newswire)
30.06.20		Number of Shares and Votes in Oncopeptides (PR Newswire)
30.06.20		Number of Shares and Votes in Oncopeptides (PR Newswire)
30.06.20		Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
30.06.20		Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
29.06.20		Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1 (PR Newswire)
29.06.20		Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1 (PR Newswire)
15.06.20		Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
15.06.20		Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
11.06.20		Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma (PR Newswire)
11.06.20		Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma (PR Newswire)
01.06.20		New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021 (PR Newswire)
01.06.20		New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021 (PR Newswire)
29.05.20		Number of shares and votes in Oncopeptides (PR Newswire)
29.05.20		Number of shares and votes in Oncopeptides (PR Newswire)
28.05.20		Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

EU-Abgeordnete fordert Bitcoin statt digitalem Euro - strategische Bitcoin-Reserve für die EU

Diese Aktien empfehlen Experten zu kaufen

APA - N A C H R I C H T E N Ü B E R B L I C K

Fed-Gouverneurin Lisa Cook und Experten sprechen klare Warnung über mögliche Korrekturen 2025 aus

Steinmeier setzt Neuwahlen für 23. Februar an

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.01.2025 12:48
Kaufwert:	EUR
	Hinzufügen Speichern